Primary atherothrombotic myocardial infarction is ischemic necrosis caused by acute coronary atherothrombosis. A plaque ruptures, loses its endothelial lining, or develops a calcified nodule; platelets and coagulation generate a thrombus that limits flow, embolizes distally, or occludes the vessel. The definition is etiological rather than electrocardiographic: the same mechanism may present as STEMI, NSTEMI, sudden cardiac arrest, or, before demonstrable necrosis, unstable angina. The urgent strategy depends on persistence of the occlusion and risk, whereas definitive classification integrates biomarkers, ECG, anatomy, and imaging.
Primary atherothrombotic myocardial infarction must not be diagnosed solely because the patient has atherosclerotic risk factors. A cardiac troponin dynamic with at least one value above the sex-specific 99th percentile and evidence of ischemia are required; the atherothrombotic mechanism must be probable or documented. In sepsis, anemia, or tachyarrhythmia, pre-existing coronary disease does not automatically make the event a primary atherothrombotic myocardial infarction. Conversely, modest residual stenosis does not exclude a complicated plaque, because the thrombus may have dissolved before coronary angiography.
Treatment has two inseparable targets: the culprit lesion and the systemic disease. PCI or bypass surgery restores flow when indicated; antiplatelet agents and anticoagulants control the thrombotic process; intensive reduction of atherogenic lipoproteins, smoking cessation, and metabolic control reduce new events throughout the vascular tree. Outcome depends not only on epicardial patency but also on the microcirculation, myocardial mass salvaged, ventricular function, and complications.
Plaque rupture often involves a fibroatheroma with a large lipid-necrotic core and a thin cap infiltrated by macrophages. Mechanical stress, matrix degradation, and inflammation exceed cap strength, bringing blood into contact with tissue factor, collagen, and thrombogenic lipids. Not all plaques with vulnerable morphology rupture, and not every rupture causes symptoms: blood thrombogenicity, injury intensity, and fibrinolysis determine the outcome. Healed ruptures may add layers of new tissue and contribute to rapid stenosis progression without an overt clinical event.
In plaque erosion, the endothelium is lost over a surface with an apparently intact cap, often rich in matrix and less lipid-rich. Disturbed flow, neutrophil activation, and innate immunity contribute to thrombosis; this phenotype is relatively more frequent in smokers, women, and younger patients than rupture. OCT operationally defines erosion when it shows adherent thrombus without cap discontinuity, but it does not directly visualize a microscopic endothelial layer. Exploratory studies have assessed antithrombotic therapy without stenting in selected erosions with noncritical stenosis, but this strategy requires expert imaging and is not a broadly applicable standard.
A calcified nodule arises from heavily calcified plaques in which fragments or sheets protrude and disrupt the surface. It is more frequent in older people, kidney disease, and tortuous segments; deep calcification makes stent expansion difficult and may require intravascular lithotripsy or other modification techniques. Thrombi also occur over plaques that cannot be clearly classified because aspiration, guidewire passage, and spontaneous resolution alter the image. Morphology guides technique, but clinical benefit derives from safely restoring flow and effective systemic prevention.
Platelet adhesion mediated by von Willebrand factor and collagen is followed by activation, ADP and thromboxane secretion, and aggregation through IIb/IIIa. Tissue factor initiates thrombin generation, which converts fibrinogen into fibrin and amplifies platelet activation; aspirin, P2Y12 inhibitors, and anticoagulants block complementary pathways, but none alone dissolves an organized obstruction as rapidly as mechanical reperfusion. Thrombus composition ranges from platelet-rich to fibrin- and erythrocyte-rich according to flow, age, and location, making the traditional distinction between white and red thrombus overly simplistic.
Cumulative exposure to apoB and LDL is causal in plaque formation; Lp(a) adds atherogenic and proinflammatory components. Smoking increases thrombosis, vasoconstriction, and oxidative stress; hypertension increases wall stress; diabetes promotes diffuse atherosclerosis, glycation, and platelet hyperreactivity; kidney disease combines calcification, inflammation, and bleeding risk. Family history and genetic variants modify age at onset. An infarction “without conventional factors” is not without a cause: subclinical burden, Lp(a), exposures, and nontraditional mechanisms should be sought. An acute precipitating factor may coexist with plaque and does not change the type when atherothrombosis is the dominant mechanism.
Reduced flow initiates the ischemic cascade: energy deficit, diastolic dysfunction, contractile loss, electrical abnormalities, and symptoms. Necrosis progresses from the subendocardium toward the epicardium as a wavefront accelerated by tachycardia, hypotension, and absence of collateral circulation; microemboli of thrombus and plaque, endothelial edema, cellular aggregates, and vasoconstriction damage the microcirculation. A TIMI 3 coronary artery after PCI may therefore coexist with no-reflow and poor tissue recovery. Early reperfusion limits scar formation but may cause stunning, arrhythmias, intramyocardial hemorrhage, and microvascular obstruction.
Plaque vulnerability is a probability, not a destiny. A thin cap, lipid core, inflammation, positive remodeling, and microcalcifications increase risk, but predictive value for an individual lesion remains limited; many events arise from plaques that were not severely stenotic before complication. A strategy of widespread preventive stenting is not justified outside research protocols. Systemic therapy reduces risk throughout the vascular bed.
Intraplaque hemorrhage expands the core through erythrocytes, membrane cholesterol, and inflammation. Fragile neovascularization and permeability promote repeated episodes, with progression even without luminal thrombosis. CMR and intravascular imaging may identify components but do not replace management of causal factors. Rapid stenosis growth may therefore precede clinical rupture.
Endogenous fibrinolysis competes with thrombus propagation. Residual flow, plasmin, fibrinolytic inhibitors, and fibrin structure determine recanalization; diabetes and inflammation may make the clot more resistant; intermittent thrombosis explains symptoms in waves and different angiographic morphologies. Antithrombotic therapy rapidly changes the finding. Imaging must be interpreted in relation to timing and drugs already administered.
The rate of thrombotic growth depends on flow: severe stenosis increases shear and platelet activation, whereas distal stasis promotes fibrin and erythrocytes. Vasoconstriction and plaque edema further reduce the lumen; composition changes along the thrombus and over time, so a single aspirated fragment does not represent the entire process. Drugs given before angiography change morphology. Pathogenesis is reconstructed by integrating all observations.
A ruptured plaque shows a cavity communicating with the lumen, a necrotic core, and superimposed thrombus; an eroded plaque shows thrombus on an irregular surface without a visible cavity; a calcified nodule contains protruding calcium. Autopsy histology remains the morphological reference, while OCT provides the best in vivo surrogate of the surface. IVUS penetrates more deeply and measures plaque burden and remodeling, but distinguishes the cap and thrombus less well. Angiography may suggest haziness, ulceration, or a filling defect without always resolving the morphology.
Culprit plaques are often concentrated in proximal segments and areas of disturbed flow, but any branch may be affected. Proximal left anterior descending artery occlusion exposes a large mass; the proximal right coronary artery may involve the right ventricle and nodal tissue; circumflex occlusion may be electrically underrepresented on the 12-lead ECG. Occlusion of a small branch may cause a limited NSTEMI, whereas left main occlusion or occlusion of the last patent vessel may cause shock with diffuse changes. Dominance and collateral circulation modify the territory without changing the atherothrombotic mechanism of primary myocardial infarction.
STEMI and NSTEMI are ECG phenotypes, not obligatory anatomical stages. A completely occlusive thrombus may recanalize before the tracing and present as NSTEMI; posterior or circumflex occlusion may not meet classic criteria; a nonocclusive thrombus may cause subendocardial ischemia. CMR shows late enhancement beginning at the endocardium and following a coronary territory, with variable depth. The presence of a transmural scar cannot be inferred from the term STEMI, and absence of a Q wave does not prove a small infarction. A complete description keeps anatomy, electrical presentation, and etiology separate.
Histologically, edema and coagulative necrosis appear, followed by neutrophil infiltration, macrophage clearance, and granulation tissue. The wall is most fragile during the days when matrix is degraded before stable collagen deposition, explaining the window for mechanical rupture; reperfusion adds contraction bands and possible hemorrhage. Stunned myocardium remains viable but hypocontractile, while the necrotic region is replaced by scar. Final size depends on time, vessel, collateral circulation, demand, and microvascular perfusion.
Thrombus organization may produce recanalization channels and plaque healing. Repeated episodes of subclinical thrombosis and repair rapidly increase volume and stenosis; conversely, complete lysis may leave a lesion below 50% and present as MINOCA. Early OCT increases the likelihood of recognizing the substrate before it heals. Absence of thrombus days later does not prove its initial absence. After PCI, stent thrombosis and restenosis within 30 days may fall under procedure-related myocardial infarction; after 30 days, if they cause myocardial infarction, they are classified as primary myocardial infarction.
Myocardial healing may progress to adverse remodeling: infarct expansion, dilation, spherical geometry, and functional mitral regurgitation. A heterogeneous scar creates slow-conduction channels for ventricular tachycardia; apical akinesia promotes thrombus; reperfusion, neurohormonal therapy, and blood-pressure control limit progression. Recovery of ejection fraction over weeks reflects resolution of stunning, not regrowth of necrotic cells. Temporal reassessment is necessary before definitive device decisions.
Neoatherosclerosis within a stent may develop macrophages, a core, and rupture; myocardial infarction caused by stent thrombosis or restenosis is procedure-related if it occurs within 30 days, whereas after 30 days it is classified as primary myocardial infarction. The biology may resemble de novo atherothrombosis, while the taxonomy distinguishes procedure-related events within 30 days from late events classified as primary myocardial infarction; this distinction helps identify underexpansion and determine antithrombotic duration. The report must name both the substrate and the type.
Plaque healing may create layers of organized tissue over silent ruptures. Repeated episodes increase plaque burden and explain rapidly progressive stenoses without a recognized syndrome. OCT sometimes shows a layered architecture but cannot date each episode precisely. Healing protects against thrombosis at that moment while simultaneously narrowing the lumen. It is a biological bridge between chronic disease and an acute event.
The microcirculation determines final infarct size independently of the lumen. Capillary density, collateral circulation, edema, emboli, and endothelial integrity modulate salvage; obstruction and hemorrhage on CMR predict remodeling; TIMI 3 does not equal normal tissue perfusion. ST-segment resolution adds a simple measure of electrical recovery, explaining different outcomes after technically similar PCI.
Scar size is the net result of the area at risk and myocardium salvaged. A proximal occlusion reperfused very early may leave less damage than a distal one treated late; collateral circulation and preconditioning modify both. CMR provides more precise measurements than the enzyme peak alone. Ejection fraction integrates remote tissue and loading conditions and may improve. Prognosis and device decisions therefore require multiple assessments.
The most common symptom is pressing or heavy chest discomfort, often radiating to the arms, shoulders, jaw, neck, back, or epigastrium. It may last more than 20 minutes, recur with intermittent occlusion, or occur at rest; response to nitrates does not identify the mechanism. Sweating, nausea, vomiting, and pallor indicate autonomic activation. Pain severity does not measure the mass at risk, and an extensive infarction may cause little pain. An episode preceded by crescendo angina suggests dynamic thrombosis, but sudden onset is common.
Dyspnea, weakness, syncope, or confusion may constitute an equivalent presentation, particularly in older people and patients with diabetes or kidney disease. Women may have typical pain together with more nausea, dyspnea, and fatigue; labeling these symptoms as noncardiac increases delay. Autonomic neuropathy may attenuate pain. Cardiac arrest or ventricular arrhythmia may precede any reliable history. In primary atherothrombotic myocardial infarction, an atherosclerotic context increases probability but need not already be known.
Physical examination defines functional extent and complications. Tachycardia, hypotension, cold extremities, and oliguria indicate hypoperfusion; crackles, a third heart sound, and hypoxia indicate congestion; jugular venous distention with clear lungs suggests right ventricular involvement; a new systolic murmur may represent mitral regurgitation or a septal defect; pulseless electrical activity may reflect free-wall rupture. None of these findings waits for biomarker classification. A normal examination is common in small infarctions and does not reduce the urgency of ECG and troponin testing.
Location influences the presentation: inferior infarction is more often associated with nausea, bradycardia, and vagal hypotension; extensive anterior infarction with heart failure, shock, intraventricular block, and apical thrombus; posterior infarction may present with anterior ST-segment depression; right ventricular infarction is preload-dependent. The culprit coronary artery cannot be determined with certainty from symptoms alone. Small territories may cause intense pain and limited biomarker elevation. Multivessel or left main ischemia may produce diffuse depression and instability without classic ST-segment elevation.
The history seeks factors suggesting mechanisms other than atherothrombosis: fever, anemia, hypoxia, and tachyarrhythmia favor secondary myocardial infarction; the puerperium and arteriopathies suggest SCAD; atrial fibrillation, endocarditis, and prosthetic valves suggest embolism; cocaine and stimulants suggest spasm or thrombosis. These factors do not exclude plaque disease but guide interpretation of angiography. A previous stent shifts suspicion toward stent thrombosis or restenosis: if the event is procedure-related within 30 days, it is classified as procedure-related myocardial infarction; after 30 days, as primary myocardial infarction. Antithrombotic drugs and their interruption are causal and safety information.
The presentation may be STEMI, NSTEMI, or cardiac death before troponin can be measured. The “type 3” category has been eliminated: when myocardial infarction is the probable cause of death before diagnostic testing, classification as primary, secondary, or procedure-related myocardial infarction must be applied according to the context or post-mortem findings. Initial clinical distinction must not delay reperfusion of an occlusion. Universal classification is refined after the emergency. A diagnosis of primary atherothrombotic myocardial infarction ultimately requires explaining to the patient the systemic nature of atherosclerosis and recurrent risk.
An anginal prodrome during the preceding hours or days may reflect intermittent thrombosis and ischemic preconditioning, but its absence is common. The history should seek a falling threshold, rest episodes, and medication interruption without delaying the ECG; sudden maximal pain at onset also suggests aortic disease or embolism and requires discriminating signs. Temporal features guide but do not prove the type.
Presentation during the puerperium or in a young woman requires consideration of SCAD, now classified as a possible non-atherothrombotic etiology of primary myocardial infarction. Treating a dissection as a plaque may propagate the hematoma and worsen flow; coronary angiography and selected imaging clarify the mechanism; conservative management is preferred when the patient is stable and flow is preserved. Absence of traditional risk factors increases the weight of this hypothesis.
In patients with kidney disease, symptoms may be atypical, baseline troponin elevated, and calcification diffuse. The dynamic and evidence of ischemia remain valid while doses and contrast are adjusted; withholding reperfusion out of concern for the kidneys may be fatal. At the same time, antithrombotic therapy and access require the greatest attention to bleeding. Both ischemic and bleeding risks are high.
Onset during physical activity does not necessarily imply secondary myocardial infarction: exertion may increase plaque stress and thrombosis in primary atherothrombotic myocardial infarction. Similarly, intense emotional stress may precipitate atherothrombosis or Takotsubo syndrome; the context is a possible trigger, not the definition of the mechanism. Anatomy, CMR, and clinical course distinguish the alternatives. Classification avoids causal shortcuts based on the immediately preceding event.
The ECG immediately separates reperfusion pathways but does not alone demonstrate the etiological type. Persistent ST-segment elevation, occlusion equivalents, dynamic ST-segment depression, or T-wave inversion indicate ischemia; serial tracings, V7-V9, and V3R-V4R recover territories not visible on the standard tracing; bundle branch block and pacing require concordance criteria and comparison with previous tracings. A normal ECG does not exclude intermittent thrombosis. Location guides coronary angiography and the search for complications without replacing anatomy.
Diagnosis of myocardial infarction requires a troponin dynamic and at least one item of evidence of ischemia. Rapid algorithms improve rule-out and rule-in in NSTE-ACS, whereas diagnostic STEMI does not await the result before reperfusion. Very high values make primary myocardial infarction more likely but overlap with secondary myocardial infarction, myocarditis, and shock. When troponin is already elevated and stable or falling, a new significant change supports a new event. The assay, sex-specific 99th percentile, and timing must be explicit. Serial cardiac troponin measurements are central when reinfarction is suspected; CK-MB does not add diagnostic clarity when troponin is available.
Diagnostic criteria for primary atherothrombotic myocardial infarction
Coronary angiography identifies occlusion, stenosis, thrombus, flow, and multivessel disease and allows treatment. A filling defect or staining suggests thrombus; resolution after aspiration or drugs strengthens the mechanism. However, a patent vessel after spontaneous lysis may retain no obvious signs. OCT characterizes the cap, erosion, thrombus, and dissection; IVUS measures diameters, plaque burden, and calcium. Imaging is particularly useful in ambiguous lesions, the left main, bifurcations, stents, and MINOCA. Instrumentation must be avoided if it adds risk without changing management.
Echocardiography documents regional abnormalities, ejection fraction, the right ventricle, valves, and complications. CMR defines the ischemic distribution of necrosis, edema, microvascular obstruction, hemorrhage, and thrombus; with nonobstructive coronary arteries it distinguishes myocarditis and Takotsubo syndrome. A subendocardial scar in a territory with OCT evidence of a complicated plaque may confirm primary atherothrombotic myocardial infarction in a patient initially classified as MINOCA. Coronary CT does not replace angiography in a high-risk event but may help when probability is low and in aortic differential diagnoses. Diagnostic testing must answer the question of mechanism rather than multiply examinations.
Secondary myocardial infarction and nonischemic myocardial injury are differential diagnoses; SCAD, embolism, and vasospasm are instead possible etiologies of primary myocardial infarction. If there is no acute coronary pathology and anemia, hypoxia, or tachyarrhythmia predominates, possible secondary myocardial infarction is considered and confirmed with Fifth UDMI criteria when imaging is feasible; if evidence of ischemia is absent, the condition is myocardial injury. SCAD shows an intramural hematoma or long narrowing and often requires conservative management; embolism may leave an otherwise normal vessel; spasm responds to nitrates and selected provocative testing. Classification may be revised when OCT, CMR, cultures, or other data become available.
An ambiguous lesion requires an orderly strategy. After flow is restored and thrombus burden reduced, OCT may show a rupture cavity, intact cap, or dissection; IVUS is preferable in the left main and for deep calcium. Imaging is not performed if instability, tortuosity, or risk makes the information unhelpful. The diagnosis may remain probabilistic when thrombus prevents visualization.
When vasospasm is suspected, response to nitrates and absence of a complicated plaque are suggestive, but provocative testing is not performed during an uncontrolled unstable event. Later, acetylcholine may document epicardial or microvascular spasm at experienced centers; spasm may overlap with plaque disease and promote thrombosis. Classification follows the demonstrated dominant mechanism. Treatment adds calcium-channel blockers and eliminates vasoconstrictors.
Testing for thrombophilia is not routine in atherothrombotic myocardial infarction. It is selected in young patients with unexplained thrombosis, recurrence, a venous history, embolism, or hematologic settings because nonspecific results during the acute phase may be misleading; antiphospholipid antibodies require confirmation over time. A positive test does not eliminate the need to characterize the plaque. Anticoagulant therapy depends on the specific diagnosis.
Angiographic thrombus is graded by burden and influences technique, but a high burden does not justify routine thrombus aspiration. Aspiration is selected when thrombus prevents flow or represents an embolus, considering stroke risk; vasodilators treat no-reflow; heparin and antiplatelet agents limit further propagation. The result is assessed with TIMI flow, blush, and ST-segment resolution. The objective is tissue perfusion, not merely luminal patency.
In primary atherothrombotic myocardial infarction with STEMI or persistent occlusion, reperfusion is the priority: primary PCI when timely, or fibrinolysis followed by transfer when appropriate criteria are met. In NSTEMI, shock, refractory pain, arrhythmias, or ischemic heart failure require immediate angiography; other patients receive an invasive strategy according to risk. Oxygen is reserved for hypoxemia, nitrates for patients with adequate blood pressure and preload, and morphine for severe persistent pain. Monitoring must allow defibrillation. Speed does not eliminate the need to exclude an aortic dissection when clinically probable.
Aspirin is loaded rapidly and combined with a P2Y12 inhibitor. Prasugrel or ticagrelor is preferred to clopidogrel in appropriate patients undergoing PCI, with contraindications and bleeding risk considered; routine pretreatment before the anatomy is known is not performed in NSTE-ACS when early angiography is planned. Unfractionated heparin is standard during PCI, while fondaparinux or enoxaparin has a role in the NSTE-ACS pathway. IIb/IIIa inhibitors are used as bailout, not routinely. Default DAPT lasts 12 months, with abbreviated or de-escalated strategies for high bleeding risk.
PCI treats the culprit lesion using radial access, a drug-eluting stent, and imaging in complex anatomy. Calcium preparation, adequate edge coverage, and good expansion prevent failure; routine thrombus aspiration does not improve outcomes and may increase stroke, but it is sometimes used as bailout. In stable STEMI with multivessel disease, complete revascularization of significant lesions reduces events; in shock, the culprit vessel is treated initially. Bypass surgery is considered for complex anatomy, left main disease, selected diabetes, or infeasible PCI. The Heart Team integrates urgency and completeness.
A high-intensity statin is started immediately; ezetimibe and additional agents achieve a very low LDL level in very-high-risk secondary prevention. The 2026 US recommendations indicate LDL below 55 mg/dL and non-HDL cholesterol below 85 mg/dL in very-high-risk patients, adapting combinations to distance from target; complete smoking cessation, blood-pressure and diabetes control, weight management, physical activity, and rehabilitation address systemic disease. Lp(a) is measured at least once to refine risk. PCI does not neutralize non-culprit plaques.
Beta-blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists are guided by ventricular function, heart failure, anterior infarction, diabetes, blood pressure, kidney function, and potassium. Contemporary heart-failure therapy is started when indicated after stabilization; ejection fraction is reassessed after stunning resolves before a primary-prevention defibrillator is considered. Rehabilitation addresses exercise, adherence, nutrition, and mental health. A written plan for DAPT and perioperative management prevents dangerous interruptions.
Prognosis depends on myocardial mass, time, shock, cardiac arrest, no-reflow, kidney function, bleeding, and anatomy. A small primary atherothrombotic myocardial infarction treated early may recover excellently; a late proximal occlusion may cause death or heart failure despite technically successful PCI. Long-term determinants include scar, multivessel disease, diabetes, Lp(a), smoking, and lipid-target attainment. Recurrence may be a new primary atherothrombotic myocardial infarction, stent thrombosis classified as procedure-related myocardial infarction within 30 days or as primary myocardial infarction after 30 days, or secondary myocardial infarction during an intercurrent illness. The new event must be classified afresh, not inherit the previous classification.
Lipid-lowering therapy aims for an early and profound reduction in atherogenic particles. A baseline measurement is obtained early, the response is checked at 4-8 weeks, and treatment is intensified without waiting for months if the gap from target is large; muscle intolerance is verified and managed with alternative doses or agents rather than abandonment of prevention. Elevated Lp(a) reinforces the intensity of overall control.
Smoking increases thrombosis and vasoconstriction, and complete cessation produces rapid benefit. Counseling, nicotine replacement or medication, and follow-up are more effective than a simple recommendation; reducing the number of cigarettes does not eliminate risk. Passive smoking and nontraditional combusted products also maintain exposure. Rehabilitation integrates treatment of dependence.
Return to activity follows an exercise prescription based on function, residual ischemia, and complications. Early rehabilitation reduces inactivity and anxiety and improves adherence; patients with heart failure or arrhythmias require greater monitoring; sexual activity and work are discussed explicitly. Prolonged generic restrictions do not protect patients and promote deconditioning. Recovery is part of the clinical outcome.
The strategy in multivessel disease depends on presentation. In stable STEMI, complete revascularization of significant lesions reduces events; in shock, initial treatment is limited to the culprit vessel. In NSTE-ACS, anatomy and risk determine timing and mode; physiology of non-culprit lesions may be altered during the acute phase and is interpreted cautiously. Bypass surgery offers completeness in complex anatomy. Kidney function guides staging.
Ventricular fibrillation and ventricular tachycardia dominate early electrical risk. Ischemia alters membrane potentials and refractoriness; the late scar creates re-entry circuits. Arrhythmias within 48 hours related to the event have a different significance from unprovoked late arrhythmias; bradycardia and block are common in inferior infarction, while infranodal block in anterior infarction indicates extensive septal injury. Atrial fibrillation worsens output and adds embolic risk. Defibrillation, reperfusion, and electrolyte correction precede chronic strategies.
Acute heart failure ranges from congestion to cardiogenic shock. Contractile loss, stunning, no-reflow, residual ischemia, mitral regurgitation, and arrhythmias contribute; echocardiography defines a left-sided, right-sided, biventricular, or mechanical phenotype; in shock, urgent revascularization of the culprit vessel is central. Vasopressors, inotropes, and mechanical support are selected according to the hemodynamic profile and experience, not applied automatically. Serial lactate and organ perfusion measure response better than blood pressure alone.
Mechanical ruptures involve the free wall, septum, and papillary muscle, particularly after extensive or late-reperfused infarctions. Tamponade, a new murmur, fulminant edema, or sudden shock requires immediate echocardiography and cardiac surgery; posteromedial papillary muscle rupture causes severe mitral regurgitation; a septal defect causes a shunt with right ventricular overload; free-wall rupture causes hemopericardium. Percutaneous or mechanical stabilization is often a bridge. Absence of a loud murmur does not exclude a communication in low output.
No-reflow and microvascular obstruction maintain hypoperfusion despite an open artery. Thrombus burden, delay, diabetes, edema, microemboli, and reperfusion injury contribute; poor ST-segment resolution and reduced blush are signs, and CMR measures the extent; intracoronary vasodilators may be attempted, but no treatment uniformly eliminates the phenomenon. Intramyocardial hemorrhage indicates severe injury. Both predict remodeling and explain the discrepancy between a good angiographic result and poor recovery.
Reinfarction, stent thrombosis, and bleeding are competing risks. Underexpansion, malapposition, edge dissection, and DAPT interruption promote thrombosis; repeat PCI with imaging corrects the mechanism. Gastrointestinal, intracranial, or access-site bleeding worsens prognosis and may require antithrombotic modification. Acute kidney injury depends on shock, congestion, and contrast; stroke may be procedural, embolic, or hemorrhagic. Correct dosing and radial access reduce avoidable harm. Every antithrombotic interruption must balance timing of stent placement against bleeding severity.
Ventricular thrombus, aneurysm, pericarditis, and remodeling emerge over days or months. Apical akinesia promotes thrombus and embolism; a true aneurysm sustains heart failure and arrhythmias; a pseudoaneurysm is a contained rupture; early pericarditis and Dressler syndrome have distinct timing and mechanisms. An extensive scar may progress to ischemic cardiomyopathy, functional mitral regurgitation, and sudden death. Depression and deconditioning impede recovery. Follow-up, selected imaging, heart-failure therapy, and secondary prevention address a risk that persists far beyond the thrombotic phase.
A contained rupture may form a pseudoaneurysm and present with persistent pain, effusion, or heart failure. Unlike a scarred true aneurysm, its wall lacks complete myocardial layers and carries a high risk of rupture; echocardiography, CT, and CMR define the neck and wall; cardiac surgery evaluates the patient promptly. It must not be mistaken for simple remodeling.
Left ventricular thrombus results from apical akinesia, endocardial injury, and hypercoagulability. Contrast echocardiography and CMR increase sensitivity, particularly after a large anterior infarction; anticoagulation is balanced against DAPT and followed by imaging to document resolution. A protruding shape and mobility increase embolic concern.
Atherothrombotic recurrence may involve the same lesion, the stent, or a different plaque. A new event requires a new classification: primary, secondary, and procedure-related myocardial infarction are not interchangeable. Uncontrolled LDL, smoking, diabetes, and antithrombotic interruption are modifiable targets. Adherence is checked with concrete questions. Prevention is continuous treatment, not advice given at discharge.
Intracranial bleeding is rare but devastating, particularly after fibrinolysis, in advanced age, and with hypertension. An acute neurological deficit requires appropriate discontinuation, imaging, and specialist treatment without delay; thrombosis and bleeding may coexist, making every decision individualized. Correction and reversal depend on the drug and timing. Prevention begins with the correct indication, dose, and blood pressure.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.